Author

V. Veninga

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:CRISPR screen· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

A. R. Bassett· 1 shared C. Dincer· 1 shared C. Hardy· 1 shared C. M. Cattaneo· 1 shared D. Ruano· 1 shared E. E. Voest· 1 shared E. Goncalves· 1 shared E. Karakoc· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. R. Bassett

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Base editing screens map mutations affecting IFNγ signalling in cancer

M. A. Coelho, E. Karakoc, S. G. Bhosle, E. Goncalves, T. Burgold, S. Cooper, C. M. Cattaneo, V. Veninga, S. Consonni, C. Dincer, S. F. Vieira, F. Gibson, S. Barthorpe, C. Hardy, J. Rein, , M. J. Garnett

This study uses base editing to identify mutations affecting IFNγ signalling in cancer, revealing loss- and gain-of-function variants with clinical relevance.

bioRxiv · Mar 29, 2022 · PreprintCancer Biology

γδ T cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects

N. L. de Vries, J. v. d. Haar, V. Veninga, M. Chalabi, M. E. Ijsselsteijn, M. v. d. Ploeg, J. v. d. Bulk, D. Ruano, J. B. Haanen, T. N. Schumacher, L. F. A. Wessels, F. Koning, N. F. C. C. de Miranda, E. E. Voest

This study shows that γδ T cells, not CD8+ T cells, mediate immune checkpoint blockade efficacy in HLA class I-negative, MMR-d colon cancers.

bioRxiv · Oct 14, 2021 · PreprintCancer Biology